FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3004878907> ?p ?o ?g. }

• W3004878907 endingPage "100228" @default.
• W3004878907 startingPage "100228" @default.
• W3004878907 abstract "Initiating varenicline use 4 weeks before the target quit date (TQD) reduces smoking in the run-in phase and increases end-treatment cessation rates; however, the lack of a smoke intake plateau suggests longer preloading periods are required. This study assessed whether varenicline preloading for 6 weeks reduced pre-quit smoke intake and enhanced 6-month abstinence outcomes compared with the standard 1-week preloading.In this randomised single-centre controlled trial, (ClinicalTrials.gov identifier: NCT02634281), conducted between February 2016 and July 2018 in Israel, daily smokers (n = 242) aged ≥ 18 years were randomly assigned (1:1) to receive varenicline preloading for 6 weeks (n = 121) or a placebo for 5 weeks followed by varenicline for 1 week (n = 121) before the TQD. Participants and researchers were masked to both group assignment and treatment allocation. Both groups received standard 12-week post-TQD varenicline treatment. The primary outcome was the 24-week biochemically verified continuous abstinence rate (CAR) from weeks 6 (TQD)-30. Secondary outcomes included the 23-week CAR from 1-week post-TQD (week 7) to week 30, and the 7-day point-prevalence (PP) abstinence at week 30. Other measures included pre- and post-quit rewards, smoking urges, nausea, aversion, and markers of cigarette consumption.By intention-to-treat, the 24-week CAR, weeks 6-30 with extended preloading was significantly higher than with standard preloading (23·1% vs. 4·1%; risk reduction [RR]: -0·19 [95% confidence interval [CI]:-0·10-0·24]; p < 0·001). Extended preloading also showed better secondary outcomes. Extended preloading significantly decreased pre-quit rewards, urges, and smoke intake, including unsolicited smoking abstinence. Post-quit urges remained remarkably lower with extended preloading. Participants receiving extended preloading reported more nausea at week 4 (39.6% vs 11.5%) and abnormal dreams at week 6 (7.7% vs. 0%). Participants receiving standard preloading reported more constipation at week 7 (7.6% vs. 0%) and dizziness at weeks 7 (12.1% vs. 2.5%) and 12 (10.7% vs 1.4%).Extended preloading reduced ad lib smoking, enhanced cessation rates at 3 and 6 months, and decreased pre- and post-quit rewards and smoking drive in a pattern compatible with a reinforcement-reduction mechanism. These data substantiate extending the standard pre-treatment period, and suggest that targeting pre-quit smoking sensations should be a treatment priority, although confirmatory evidence is needed from larger clinical trials.This study was funded by a 2013 Global Research Award for Nicotine Dependence (GRAND) supported by Pfizer, Inc. (#WI182915)." @default.
• W3004878907 created "2020-02-14" @default.
• W3004878907 creator A5036274796 @default.
• W3004878907 creator A5051396924 @default.
• W3004878907 creator A5058843405 @default.
• W3004878907 creator A5079457578 @default.
• W3004878907 creator A5085038232 @default.
• W3004878907 date "2020-02-01" @default.
• W3004878907 modified "2023-10-06" @default.
• W3004878907 title "Extending varenicline preloading to 6 weeks facilitates smoking cessation: A single-site, randomised controlled trial" @default.
• W3004878907 cites W1859891561 @default.
• W3004878907 cites W1976653331 @default.
• W3004878907 cites W1978524840 @default.
• W3004878907 cites W1985791213 @default.
• W3004878907 cites W2003078192 @default.
• W3004878907 cites W2030674555 @default.
• W3004878907 cites W2032541700 @default.
• W3004878907 cites W2045213593 @default.
• W3004878907 cites W2056242904 @default.
• W3004878907 cites W2074854406 @default.
• W3004878907 cites W2084289344 @default.
• W3004878907 cites W2099217132 @default.
• W3004878907 cites W2107200746 @default.
• W3004878907 cites W2115129983 @default.
• W3004878907 cites W2118061336 @default.
• W3004878907 cites W2159009822 @default.
• W3004878907 cites W2164386461 @default.
• W3004878907 cites W2171937180 @default.
• W3004878907 cites W2322180695 @default.
• W3004878907 cites W2417827962 @default.
• W3004878907 cites W2512612747 @default.
• W3004878907 cites W2529083828 @default.
• W3004878907 cites W2887709599 @default.
• W3004878907 doi "https://doi.org/10.1016/j.eclinm.2019.11.021" @default.
• W3004878907 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7005428" @default.
• W3004878907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32055787" @default.
• W3004878907 hasPublicationYear "2020" @default.
• W3004878907 type Work @default.
• W3004878907 sameAs 3004878907 @default.
• W3004878907 citedByCount "9" @default.
• W3004878907 countsByYear W30048789072020 @default.
• W3004878907 countsByYear W30048789072021 @default.
• W3004878907 countsByYear W30048789072022 @default.
• W3004878907 countsByYear W30048789072023 @default.
• W3004878907 crossrefType "journal-article" @default.
• W3004878907 hasAuthorship W3004878907A5036274796 @default.
• W3004878907 hasAuthorship W3004878907A5051396924 @default.
• W3004878907 hasAuthorship W3004878907A5058843405 @default.
• W3004878907 hasAuthorship W3004878907A5079457578 @default.
• W3004878907 hasAuthorship W3004878907A5085038232 @default.
• W3004878907 hasBestOaLocation W30048789071 @default.
• W3004878907 hasConcept C118552586 @default.
• W3004878907 hasConcept C126322002 @default.
• W3004878907 hasConcept C142724271 @default.
• W3004878907 hasConcept C168563851 @default.
• W3004878907 hasConcept C1862650 @default.
• W3004878907 hasConcept C204787440 @default.
• W3004878907 hasConcept C207103383 @default.
• W3004878907 hasConcept C27081682 @default.
• W3004878907 hasConcept C2777053506 @default.
• W3004878907 hasConcept C2777843972 @default.
• W3004878907 hasConcept C2780580376 @default.
• W3004878907 hasConcept C2780687700 @default.
• W3004878907 hasConcept C42219234 @default.
• W3004878907 hasConcept C44249647 @default.
• W3004878907 hasConcept C71924100 @default.
• W3004878907 hasConceptScore W3004878907C118552586 @default.
• W3004878907 hasConceptScore W3004878907C126322002 @default.
• W3004878907 hasConceptScore W3004878907C142724271 @default.
• W3004878907 hasConceptScore W3004878907C168563851 @default.
• W3004878907 hasConceptScore W3004878907C1862650 @default.
• W3004878907 hasConceptScore W3004878907C204787440 @default.
• W3004878907 hasConceptScore W3004878907C207103383 @default.
• W3004878907 hasConceptScore W3004878907C27081682 @default.
• W3004878907 hasConceptScore W3004878907C2777053506 @default.
• W3004878907 hasConceptScore W3004878907C2777843972 @default.
• W3004878907 hasConceptScore W3004878907C2780580376 @default.
• W3004878907 hasConceptScore W3004878907C2780687700 @default.
• W3004878907 hasConceptScore W3004878907C42219234 @default.
• W3004878907 hasConceptScore W3004878907C44249647 @default.
• W3004878907 hasConceptScore W3004878907C71924100 @default.
• W3004878907 hasLocation W30048789071 @default.
• W3004878907 hasLocation W30048789072 @default.
• W3004878907 hasLocation W30048789073 @default.
• W3004878907 hasLocation W30048789074 @default.
• W3004878907 hasLocation W30048789075 @default.
• W3004878907 hasOpenAccess W3004878907 @default.
• W3004878907 hasPrimaryLocation W30048789071 @default.
• W3004878907 hasRelatedWork W1547289621 @default.
• W3004878907 hasRelatedWork W17125558 @default.
• W3004878907 hasRelatedWork W2034229369 @default.
• W3004878907 hasRelatedWork W2337003553 @default.
• W3004878907 hasRelatedWork W2351385512 @default.
• W3004878907 hasRelatedWork W2801196213 @default.
• W3004878907 hasRelatedWork W2981998278 @default.
• W3004878907 hasRelatedWork W3123815595 @default.
• W3004878907 hasRelatedWork W3128482304 @default.
• W3004878907 hasRelatedWork W4220698926 @default.

• next